If one modality has defined oncology dealmaking in recent years, it is the antibody-drug conjugate. Once a promising niche, ADCs have become a commercial powerhouse and the single hottest category in cancer drug development, drawing tens of billions of dollars in acquisitions and licensing. Here is the state of play in 2026: the drugs driving it, the deals reshaping it, the companies leading it, and the challenges that still lie ahead.
A quick refresher on what an ADC is
An antibody-drug conjugate is often described as a “guided missile” for cancer. It joins a targeting antibody to a potent cancer-killing drug using a chemical linker: the antibody finds the tumor, and the linker releases the toxic payload where it can do the most damage while sparing healthy tissue. This combination of precise targeting and powerful killing is what makes ADCs so effective, and why they have become one of the most important tools in modern oncology.
The market has become a powerhouse
The numbers tell the story. The ADC market reached well over ten billion dollars in annual sales, with a growing roster of approved products and an extraordinarily active pipeline, with hundreds of candidates in clinical development. ADCs have expanded well beyond their early strongholds into a widening range of solid tumors, dramatically increasing the number of patients they can help. This is no longer an emerging category; it is a core pillar of oncology, and its growth has been fast enough to make it a strategic priority for essentially every major cancer drugmaker.
The flagship: Enhertu and the platform behind it
The drug that best symbolizes the ADC era is Enhertu, developed by Daiichi Sankyo and AstraZeneca, which has become the best-selling ADC and continues to expand into new patient populations and earlier lines of treatment. Just as important as the drug is the platform behind it: Daiichi Sankyo’s linker-payload technology powers a family of ADCs targeting different tumor markers, and the company has turned that platform into a series of lucrative partnerships. The success of this platform, more than any single drug, is what convinced the industry that ADCs were a durable, repeatable source of value rather than a one-off.
The deals reshaping the field
The scramble for ADC assets has produced some of the largest transactions in recent pharma history.
- Pfizer’s acquisition of Seagen, valued at roughly $43 billion, was the defining ADC deal, giving Pfizer control of multiple approved ADCs and a deep pipeline.
- AbbVie’s acquisition of ImmunoGen brought it an approved ovarian cancer ADC and further validated the category’s premium valuations.
- The ongoing Daiichi Sankyo partnerships, including large collaborations with AstraZeneca and others, have moved billions of dollars and spread the company’s platform across the industry.
These deals reflect a simple calculation: with patent cliffs looming and ADCs proven to work, big pharma has decided it is faster and safer to buy or partner for ADC assets than to build from scratch.
The China factor
One of the most striking developments is the rise of China as an ADC powerhouse. Chinese biotechs have built deep expertise in the linker and payload chemistry at the heart of ADCs, and they now account for a large share of global ADC licensing activity, with companies like Kelun-Biotech, Duality, and MediLink becoming familiar names to oncology dealmakers. For Western pharma building an ADC pipeline, China has become a primary hunting ground for assets, a trend that sits within the broader wave of licensing deals flowing out of Chinese biotech.
The challenges that remain
For all the excitement, ADCs are not a solved problem, and the challenges are real. Safety is a persistent concern, since even a well-targeted ADC can cause serious side effects, and improving the therapeutic window remains a central goal of next-generation designs. Manufacturing is genuinely hard: building an ADC means combining a biologic antibody, a toxic small-molecule payload, and a linker at pharmaceutical quality and scale, which demands specialized capabilities and capacity that are in short supply. And pricing and access are challenges, as these are expensive therapies. The next wave of innovation, novel targets, better payloads and linkers, and more sophisticated formats like bispecific and dual-payload ADCs, is aimed squarely at widening the gap between killing tumors and harming patients.
The bottom line
ADCs in 2026 are a proven, booming, fiercely competitive category, anchored by flagship drugs and platforms, fueled by mega-deals, increasingly sourced from China, and pushing toward ever more sophisticated designs. They have moved from promising modality to core oncology pillar, and the deal activity shows no sign of slowing. The companies that will lead the next chapter are those that can pair genuine innovation in targets and payloads with the specialized manufacturing muscle these complex drugs demand, because in ADCs, the science and the ability to actually make the drug are inseparable.
The next generation of ADC design
The current wave of approved ADCs, powerful as it is, represents an early chapter, and the innovation aimed at the next generation is where much of the field’s future value lies. Several directions stand out. Developers are engineering better linkers and novel payloads to widen the therapeutic window, the crucial gap between killing the tumor and harming the patient, since safety remains the modality’s central limitation. They are building bispecific and biparatopic ADCs that engage two targets or two sites on a target at once, aiming for greater precision and potency. They are exploring new classes of payload beyond traditional cell-killing toxins, including payloads that stimulate the immune system to attack the tumor, blurring the line between ADCs and immunotherapy. And they are pushing into new targets, unlocking cancers and patient populations that current ADCs cannot reach. There is also early interest in applying the guided-delivery concept beyond oncology, using antibodies to deliver payloads in other diseases, which could eventually broaden the modality well past cancer. Underlying all of this is the reality that ADCs are among the most technically demanding drugs to design and make, so progress depends as much on advances in chemistry, engineering, and manufacturing as on biology. The companies that master the next-generation design challenges, cleaner linkers, smarter payloads, more sophisticated formats, while building or securing the specialized manufacturing to produce them, will lead the field’s second act. Given how much capital and talent is flowing in, that next chapter is likely to arrive quickly, and it will determine whether ADCs continue their remarkable expansion or run into the ceilings that constrain every modality eventually.
The manufacturing reality behind the boom
A theme that runs through the entire ADC story, and that is easy to overlook amid the deals and data, is how central and difficult manufacturing is to this modality. An ADC is genuinely hard to make: it requires producing a biologic antibody, synthesizing a highly potent, often toxic payload, and joining them with a linker, all to exacting pharmaceutical standards and at commercial scale, while handling dangerous materials safely. This complexity means specialized manufacturing capability is a real competitive advantage and a genuine bottleneck, since the capacity to make ADCs to the required standard is limited and in high demand. It is a major reason ADC development is as much a manufacturing challenge as a scientific one, and why the makers and specialized contract manufacturers with proven conjugation expertise are so strategically important to the field. For a company developing an ADC, securing reliable, high-quality manufacturing is not a downstream detail but a core determinant of whether the program succeeds, and the scarcity of that capacity shapes timelines and partnerships across the industry. As the ADC pipeline continues to swell with hundreds of candidates, the pressure on manufacturing capacity will only intensify, making the ability to actually produce these drugs one of the defining constraints on how fast the category can grow.
Because ADC manufacturing is such a specialized challenge, the makers and CDMOs with real conjugation expertise are central to the field; browse them in the BioMed Nexus CDMO directory. For the science behind these drugs, see our field guide to antibody drugs, and the daily brief tracks the deals and data as they land.
Frequently asked questions
What is an antibody-drug conjugate (ADC)?
An antibody-drug conjugate is a cancer drug that joins a targeting antibody to a potent cancer-killing payload using a chemical linker. The antibody delivers the toxic payload directly to tumor cells while largely sparing healthy tissue, combining precise targeting with powerful killing. ADCs are often described as guided missiles for cancer.
What was the biggest ADC deal?
Pfizer's acquisition of Seagen, valued at roughly $43 billion, was the defining ADC deal, giving Pfizer control of multiple approved ADCs and a deep pipeline. Other major transactions include AbbVie's acquisition of ImmunoGen and the large ongoing partnerships built around Daiichi Sankyo's linker-payload platform, including with AstraZeneca.
What is the best-selling antibody-drug conjugate?
Enhertu, developed by Daiichi Sankyo and AstraZeneca, is the best-selling ADC. It continues to expand into new patient populations and earlier lines of treatment, and the linker-payload platform behind it powers a family of additional ADCs targeting different tumor markers, which the company has turned into a series of major partnerships.
